Merck KGaA (MRK.DE) Stock
Merck KGaA

Company profile
Merck KGaA reported revenue of 21.10 billion EUR for fiscal year 2025, down 0.3% from fiscal year 2024, and net income of 2.61 billion EUR. That is a net profit margin of 12.4% for fiscal year 2025. Its largest business segment, Life Science, brought in 43% of segment revenue in fiscal year 2025; USA was the largest region with 26%. Our analysis of its filings shows revenue growing from 20.99 billion EUR in fiscal year 2023 to 21.10 billion EUR in fiscal year 2025, 0.3% a year on average. Merck KGaA reports about 62,136 full-time employees.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Largest shareholders
- First Eagle Investment Management LLC5.12%
- Amundi Asset Management SAS (Investment Management)3.10%
- Mondrian Investment Partners Ltd.3.10%
- Goldman Sachs Asset Management International0.48%
- Allianz Global Investors GmbH (France)0.18%
Share of the company, as of September 25, 2026
Leadership
- Kai Beckmann — CEO & Chair of Management Board, 60
- Danny Pinhas Bar-Zohar M.D. — Member of the Executive Board & CEO of Healthcare, 55
- Jean Charles Wirth — Member of the Executive Board & CEO Life Science, 52
- Benjamin Hein — Member of Management Board & CEO of Electronics Business Sector
- Helene von Roeder — CFO & Member of Executive Board, 55
How much revenue does Merck KGaA make?
Merck KGaA reported 21.10 billion EUR in revenue for fiscal year 2025, down 0.3% from 21.16 billion EUR in fiscal year 2024.
What is Merck KGaA's largest business segment?
Life Science, with 9.09 billion EUR or 43% of segment revenue in fiscal year 2025. Next: Healthcare (41%) and Electronics (17%).
Where does Merck KGaA make most of its revenue?
USA: 26% of revenue by region in fiscal year 2025, followed by Other Europe (22%).
What companies are similar to Merck KGaA?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bayer Aktiengesellschaft (BAYN.DE), Dermapharm Holding SE (DMP.DE), Biotest Aktiengesellschaft (BIO3.DE), Cannovum Cannabis AG (27N0.DE).
Company Information
Data as of .
How to cite: DataPorium, “Merck KGaA (MRK.DE)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/MRK.DE